Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy-free, first-line treatment for PD-L1-positive non-small cell lung cancer.
Yixin ZhouYaqiong ZhangGuifang GuoXiuyu CaiHui YuYanyu CaiBei ZhangShaodong HongLi ZhangPublished in: Clinical and translational medicine (2020)
N-I and PEM provide comparable OS benefit for PD-L1-positive NSCLC. N-I further improves PFS relative to PEM but at meaningful cost of toxicities.